<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults: Traditional regimen (minimum six months)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults: Traditional regimen (minimum six months)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults: Traditional regimen (minimum six months)</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="2">Intensive phase*</td> <td class="subtitle1" colspan="2">Continuation phase<sup>¶</sup></td> <td class="subtitle1_left" rowspan="2">Range of total doses<br/> (minimal duration)</td> <td class="subtitle1_left" rowspan="2">Comments<sup>Δ◊</sup></td> </tr> <tr> <td class="subtitle2_left">Drugs</td> <td class="subtitle2_left">Interval and doses<sup>§</sup><br/> (minimal duration)</td> <td class="subtitle2_left">Drugs</td> <td class="subtitle2_left">Interval and doses<sup>§</sup><br/> (minimal duration)</td> </tr> <tr> <td class="subtitle3_left_align" colspan="6">Regimen 1</td> </tr> <tr> <td class="indent1"> <p>INH</p> <p>RIF</p> <p>PZA</p> EMB</td> <td> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or</p> 5 days per week for 40 doses (8 weeks)<sup>¥</sup></td> <td> <p>INH</p> RIF</td> <td> <p>7 days per week for 126 doses (18 weeks), or</p> 5 days per week for 90 doses (18 weeks)</td> <td>182 to 130 (26 weeks)</td> <td>This is the preferred regimen for patients with newly diagnosed pulmonary tuberculosis.</td> </tr> <tr> <td class="subtitle3_left_align" colspan="6">Regimen 2</td> </tr> <tr> <td class="indent1"> <p>INH</p> <p>RIF</p> <p>PZA</p> EMB</td> <td> <p><strong>Daily for 8 weeks</strong></p> <p>7 days per week for 56 doses (8 weeks), or</p> 5 days per week for 40 doses (8 weeks)<sup>¥</sup></td> <td> <p>INH</p> RIF</td> <td>Three times weekly for 54 doses (18 weeks)</td> <td>110 to 94 (26 weeks)</td> <td>Preferred alternative regimen in situations in which more frequent DOT during continuation phase is difficult to achieve.</td> </tr> <tr> <td class="subtitle3_left_align" colspan="6">Regimen 3</td> </tr> <tr> <td class="indent1"> <p>INH</p> <p>RIF</p> <p>PZA</p> EMB</td> <td> <p><strong>Three times weekly for 8 weeks</strong></p> Three times weekly for 24 doses (8 weeks)</td> <td> <p>INH</p> RIF</td> <td>Three times weekly for 54 doses (18 weeks)</td> <td>78 (26 weeks)</td> <td>Use regimen with caution in patients with HIV and/or cavitary disease. Missed doses can lead to treatment failure, relapse, and acquired drug resistance.</td> </tr> <tr> <td class="subtitle3_left_align" colspan="6">Regimen 4</td> </tr> <tr> <td class="indent1"> <p>INH</p> <p>RIF</p> <p>PZA</p> EMB</td> <td> <p><strong>Daily for 2 weeks, then twice weekly for 6 weeks</strong></p> 7 days per week for 14 doses (2 weeks), then twice weekly for 12 doses<sup>‡</sup></td> <td> <p>INH</p> RIF</td> <td>Twice weekly for 36 doses (18 weeks)</td> <td>62 (26 weeks)</td> <td>Do not use twice-weekly regimens in HIV-infected patients or patients with smear-positive and/or cavitary disease. If doses are missed, then therapy is equivalent to once weekly, which is inferior.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>INH: isoniazid; RIF: rifampin; RPT: rifapentine; PZA: pyrazinamide; EMB: ethambutol; DOT: directly observed therapy; HIV: human immunodeficiency virus.</p>
<p>* Daily therapy is preferred over intermittent therapy to reduce risk of relapse and drug resistance; this is particularly important during the intensive phase of treatment.</p>
<p>¶ During the continuation phase of treatment, daily treatment is preferred over intermittent therapy; if daily therapy is not feasible, thrice-weekly dosing is preferred over twice-weekly dosing.</p>
<p>Δ Based on expert opinion, patients with cavitation on initial chest radiograph and positive cultures at completion of two months of therapy should receive a seven-month (31-week) continuation phase.</p>
<p>◊ Pyridoxine (vitamin B6; 25 to 50 mg/day) is given with isoniazid to individuals at risk for neuropathy (eg, pregnant women, breastfeeding infants, and individuals with HIV infection, diabetes, alcoholism, malnutrition, chronic renal failure, or advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.</p>
<p>§ When DOT is used, drugs may be given five days per week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicates that this is an effective practice. DOT should be used when drugs are administered &lt;7 days per week.</p>
<p>¥ Five-day-a-week administration is always given by DOT.</p>
‡ Alternatively, some United States tuberculosis control programs have administered intensive-phase regimens 5 days per week for 15 doses (3 weeks), then twice weekly for 12 doses.</div><div class="graphic_reference">Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195. By permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2016. <a href="https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/" target="_blank">https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/</a>.</div><div id="graphicVersion">Graphic 50102 Version 28.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
